Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...
Please provide your email address to receive an email when new articles are posted on . Pirtobrutinib significantly improved PFS for patients with CLL and SLL compared with standard chemoimmunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback